Agilent Technologies (A) Earns “Buy” Rating from Barclays
Agilent Technologies (NYSE:A)‘s stock had its “buy” rating reiterated by research analysts at Barclays in a report released on Monday. They presently have a $74.00 target price on the medical research company’s stock. Barclays’ target price would indicate a potential upside of 3.11% from the stock’s previous close.
A number of other brokerages also recently commented on A. JPMorgan Chase & Co. boosted their target price on Agilent Technologies to $75.00 and gave the company an “overweight” rating in a research note on Tuesday, November 21st. Deutsche Bank set a $75.00 price target on Agilent Technologies and gave the stock a “buy” rating in a research report on Tuesday, November 21st. Cowen reaffirmed a “hold” rating and issued a $70.00 price target on shares of Agilent Technologies in a research report on Wednesday, November 22nd. ValuEngine cut Agilent Technologies from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Finally, Robert W. Baird reaffirmed a “buy” rating and issued a $72.00 price target on shares of Agilent Technologies in a research report on Friday, November 24th. Six equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $68.98.
Agilent Technologies (NYSE A) opened at $71.77 on Monday. The company has a debt-to-equity ratio of 0.37, a current ratio of 3.30 and a quick ratio of 2.85. Agilent Technologies has a 52 week low of $47.05 and a 52 week high of $72.33. The company has a market capitalization of $23,100.00, a PE ratio of 34.34, a price-to-earnings-growth ratio of 2.11 and a beta of 1.28.
Agilent Technologies (NYSE:A) last issued its earnings results on Monday, November 20th. The medical research company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.05. Agilent Technologies had a return on equity of 16.95% and a net margin of 15.30%. The firm had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the previous year, the company posted $0.59 earnings per share. The business’s quarterly revenue was up 7.0% compared to the same quarter last year. equities research analysts forecast that Agilent Technologies will post 2.58 EPS for the current fiscal year.
In related news, CEO Michael R. Mcmullen sold 43,703 shares of the business’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $70.00, for a total transaction of $3,059,210.00. Following the completion of the transaction, the chief executive officer now owns 302,837 shares of the company’s stock, valued at approximately $21,198,590. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Didier Hirsch sold 12,964 shares of the business’s stock in a transaction dated Wednesday, November 22nd. The stock was sold at an average price of $69.00, for a total value of $894,516.00. Following the transaction, the chief financial officer now directly owns 184,851 shares of the company’s stock, valued at approximately $12,754,719. The disclosure for this sale can be found here. Insiders sold 176,291 shares of company stock valued at $12,245,920 in the last ninety days.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Dupont Capital Management Corp bought a new position in Agilent Technologies during the third quarter valued at about $101,000. Balentine LLC increased its stake in Agilent Technologies by 2.9% during the second quarter. Balentine LLC now owns 1,794 shares of the medical research company’s stock valued at $106,000 after acquiring an additional 50 shares during the period. Sun Life Financial INC increased its stake in Agilent Technologies by 26,144.4% during the second quarter. Sun Life Financial INC now owns 2,362 shares of the medical research company’s stock valued at $140,000 after acquiring an additional 2,353 shares during the period. Acrospire Investment Management LLC increased its stake in Agilent Technologies by 92.3% during the second quarter. Acrospire Investment Management LLC now owns 2,500 shares of the medical research company’s stock valued at $148,000 after acquiring an additional 1,200 shares during the period. Finally, Fiduciary Trust Co. bought a new position in Agilent Technologies during the second quarter valued at about $186,000.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Watch List News and is the property of of Watch List News. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://www.watchlistnews.com/agilent-technologies-a-earns-buy-rating-from-barclays/1800961.html.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with Analyst Ratings Network's FREE daily email newsletter.